EP3399996A4 - Verfahren zur verabreichung von hepcidin - Google Patents

Verfahren zur verabreichung von hepcidin Download PDF

Info

Publication number: EP3399996A4
Authority: EP; European Patent Office
Prior art keywords: methods; administering hepcidin; hepcidin; administering
Prior art date: 2016-01-08
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP17736393.4A

Other languages

English (en)

French (fr)

Other versions

EP3399996A1 (de

Inventor

George Tidmarsh

Lakhmir Chawla

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

La Jolla Pharmaceutical Co

Original Assignee

La Jolla Pharmaceutical Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-01-08

Filing date

2017-01-06

Publication date

2019-10-16

2017-01-06 Application filed by La Jolla Pharmaceutical Co filed Critical La Jolla Pharmaceutical Co

2018-11-14 Publication of EP3399996A1 publication Critical patent/EP3399996A1/de

2019-10-16 Publication of EP3399996A4 publication Critical patent/EP3399996A4/de

Status Withdrawn legal-status Critical Current

Links

XJOTXKZIRSHZQV-RXHOOSIZSA-N (3S)-3-amino-4-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S,3S)-1-[[(1R,6R,12R,17R,20S,23S,26R,31R,34R,39R,42S,45S,48S,51S,59S)-51-(4-aminobutyl)-31-[[(2S)-6-amino-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-1-oxohexan-2-yl]carbamoyl]-20-benzyl-23-[(2S)-butan-2-yl]-45-(3-carbamimidamidopropyl)-48-(hydroxymethyl)-42-(1H-imidazol-4-ylmethyl)-59-(2-methylsulfanylethyl)-7,10,19,22,25,33,40,43,46,49,52,54,57,60,63,64-hexadecaoxo-3,4,14,15,28,29,36,37-octathia-8,11,18,21,24,32,41,44,47,50,53,55,58,61,62,65-hexadecazatetracyclo[32.19.8.26,17.212,39]pentahexacontan-26-yl]amino]-3-methyl-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-4-oxobutanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)[C@@H](C)O)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@@H]4CSSC[C@H](NC(=O)[C@H](Cc5ccccc5)NC(=O)[C@@H](NC1=O)[C@@H](C)CC)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc1cnc[nH]1)NC3=O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N2)C(=O)NCC(=O)N4)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XJOTXKZIRSHZQV-RXHOOSIZSA-N 0.000 title 1
102000018511 hepcidin Human genes 0.000 title 1
229940066919 hepcidin Drugs 0.000 title 1
108060003558 hepcidin Proteins 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Diabetes (AREA)
Tropical Medicine & Parasitology (AREA)
Zoology (AREA)
Hematology (AREA)
Virology (AREA)
Endocrinology (AREA)
Marine Sciences & Fisheries (AREA)
Dermatology (AREA)
Molecular Biology (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Biotechnology (AREA)
Pulmonology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

EP17736393.4A 2016-01-08 2017-01-06 Verfahren zur verabreichung von hepcidin Withdrawn EP3399996A4 (de)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
US201662276727P	2016-01-08	2016-01-08
US201662276922P	2016-01-10	2016-01-10
US201662287285P	2016-01-26	2016-01-26
US201662400795P	2016-09-28	2016-09-28
US201662436070P	2016-12-19	2016-12-19
PCT/US2017/012454 WO2017120419A1 (en)	2016-01-08	2017-01-06	Methods of administering hepcidin

Publications (2)

Publication Number	Publication Date
EP3399996A1 EP3399996A1 (de)	2018-11-14
EP3399996A4 true EP3399996A4 (de)	2019-10-16

Family

ID=59274194

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP17736393.4A Withdrawn EP3399996A4 (de)	2016-01-08	2017-01-06	Verfahren zur verabreichung von hepcidin

Country Status (12)

Country	Link
US (2)	US20170246256A1 (de)
EP (1)	EP3399996A4 (de)
JP (1)	JP2019505517A (de)
KR (1)	KR20180109917A (de)
CN (1)	CN108883154A (de)
AU (1)	AU2017205633A1 (de)
BR (1)	BR112018013833A2 (de)
CA (1)	CA3010708A1 (de)
MX (1)	MX2018008299A (de)
PH (1)	PH12018501443A1 (de)
SG (1)	SG11201805755SA (de)
WO (1)	WO2017120419A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA3035234A1 (en) *	2016-09-06	2018-03-15	La Jolla Pharmaceutical Company	Methods of treating iron overload
WO2018107241A1 (en) *	2016-12-16	2018-06-21	The University Of Sydney	Treatment of iron disorders
AU2017378976A1 (en) *	2016-12-19	2019-07-04	La Jolla Pharmaceutical Company	Methods of administering hepcidin
CN110520147A (zh) *	2017-01-18	2019-11-29	拉卓拉药物公司	用于治疗铁过载的组合物和方法
WO2018175633A1 (en) *	2017-03-22	2018-09-27	La Jolla Pharmaceutical Company	Methods of inducing anti-malarial immune responses and compositions related thereto
US20190315821A1 (en) *	2018-02-23	2019-10-17	La Jolla Pharmaceutical Company	Compositions comprising hepcidin and methods of use thereof
US20210169985A1 (en) *	2018-05-04	2021-06-10	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for treating gram positive bacterial infection
CN112336745A (zh) *	2019-08-09	2021-02-09	清华大学	含铁物质在制备抑制登革热病毒传播的产品中的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2002098444A2 (en) *	2001-05-25	2002-12-12	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis
WO2010065815A2 (en) *	2008-12-05	2010-06-10	The Regents Of The University Of California	Mini-hepcidin peptides and methods of using thereof
WO2013086143A1 (en) *	2011-12-09	2013-06-13	The Regents Of The University Of California	Modified mini-hepcidin peptides and methods of using thereof
WO2015033345A1 (en) *	2013-09-08	2015-03-12	Rappaport Family Institute For Research In The Medical Sciences	Semaphorin 3c variants, compositions comprising said variants and methods of use thereof
WO2015200916A2 (en) *	2014-06-27	2015-12-30	Protagonist Therapeutics, Inc.	Hepcidin and mini-hepcidin analogues and uses therof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2948283A1 (en) *	2014-04-07	2015-10-15	Merganser Biotech, Inc.	Hepcidin mimetic peptides and uses thereof
CA2970962A1 (en) *	2014-12-29	2016-07-07	The Regents Of The University Of California	S-alkylated hepcidin peptides and methods of making and using thereof

2017
- 2017-01-06 CA CA3010708A patent/CA3010708A1/en not_active Abandoned
- 2017-01-06 EP EP17736393.4A patent/EP3399996A4/de not_active Withdrawn
- 2017-01-06 JP JP2018535331A patent/JP2019505517A/ja active Pending
- 2017-01-06 SG SG11201805755SA patent/SG11201805755SA/en unknown
- 2017-01-06 MX MX2018008299A patent/MX2018008299A/es unknown
- 2017-01-06 AU AU2017205633A patent/AU2017205633A1/en not_active Abandoned
- 2017-01-06 WO PCT/US2017/012454 patent/WO2017120419A1/en not_active Ceased
- 2017-01-06 US US15/399,936 patent/US20170246256A1/en not_active Abandoned
- 2017-01-06 KR KR1020187022493A patent/KR20180109917A/ko not_active Withdrawn
- 2017-01-06 CN CN201780015868.0A patent/CN108883154A/zh active Pending
- 2017-01-06 BR BR112018013833A patent/BR112018013833A2/pt not_active Application Discontinuation
2018
- 2018-07-05 PH PH12018501443A patent/PH12018501443A1/en unknown
2019
- 2019-03-21 US US16/360,838 patent/US20190240292A1/en not_active Abandoned

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2002098444A2 (en) *	2001-05-25	2002-12-12	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis
WO2010065815A2 (en) *	2008-12-05	2010-06-10	The Regents Of The University Of California	Mini-hepcidin peptides and methods of using thereof
WO2013086143A1 (en) *	2011-12-09	2013-06-13	The Regents Of The University Of California	Modified mini-hepcidin peptides and methods of using thereof
WO2015033345A1 (en) *	2013-09-08	2015-03-12	Rappaport Family Institute For Research In The Medical Sciences	Semaphorin 3c variants, compositions comprising said variants and methods of use thereof
WO2015200916A2 (en) *	2014-06-27	2015-12-30	Protagonist Therapeutics, Inc.	Hepcidin and mini-hepcidin analogues and uses therof

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BLOOD, vol. 122, no. 21, November 2013 (2013-11-01), 55TH ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY; NEW ORLEANS, LA, USA; DECEMBER 07 -10, 2013, pages 431, ISSN: 0006-4971(print) *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; November 2013 (2013-11-01), CASU CARLA ET AL: "Treatment With Minihepcidin Peptide Improves Anemia and Iron Overload In a Mouse Model Of Thalassemia Intermedia", XP002793975, Database accession no. PREV201400359589 *
EMILIO RAMOS ET AL: "Minihepcidins prevent iron overload in a hepcidin-deficient mouse model of severe hemochromatosis", BLOOD, vol. 120, 1 January 2012 (2012-01-01), pages 3829 - 3836, XP055618018, DOI: 10.1182/blood-2012- *
HUNTER HOWARD N ET AL: "The solution structure of human hepcidin, a peptide hormone with antimicrobial activity that is involved in iron uptake and hereditary hemochromatosis", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 277, no. 40, 4 October 2002 (2002-10-04), pages 37597 - 37603, XP002519930, ISSN: 0021-9258, [retrieved on 20020722], DOI: 10.1074/JBC.M205305200 *
See also references of WO2017120419A1 *
UNIVERSITY OF CALIFORNIA - LOS ANGELES: "Scientists design experimental treatment for iron-overload diseases", 1 November 2011 (2011-11-01), Medical Xpress, XP055618009, Retrieved from the Internet <URL:https://medicalxpress.com/pdf239370231.pdf> [retrieved on 20190903] *

Also Published As

Publication number	Publication date
SG11201805755SA (en)	2018-08-30
BR112018013833A2 (pt)	2018-12-11
CN108883154A (zh)	2018-11-23
CA3010708A1 (en)	2017-07-13
US20190240292A1 (en)	2019-08-08
JP2019505517A (ja)	2019-02-28
EP3399996A1 (de)	2018-11-14
AU2017205633A1 (en)	2018-08-16
WO2017120419A1 (en)	2017-07-13
PH12018501443A1 (en)	2019-03-11
MX2018008299A (es)	2018-09-21
US20170246256A1 (en)	2017-08-31
KR20180109917A (ko)	2018-10-08

Legal Events

Date	Code	Title	Description
2017-07-14	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE
2018-10-12	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2018-10-12	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2018-11-14	17P	Request for examination filed	Effective date: 20180801
2018-11-14	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2018-11-14	AX	Request for extension of the european patent	Extension state: BA ME
2018-12-12	RIN1	Information on inventor provided before grant (corrected)	Inventor name: CHAWLA, LAKHMIR Inventor name: TIDMARSH, GEORGE
2019-04-17	DAV	Request for validation of the european patent (deleted)
2019-04-17	DAX	Request for extension of the european patent (deleted)
2019-10-16	A4	Supplementary search report drawn up and despatched	Effective date: 20190918
2019-10-16	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 38/17 20060101AFI20190910BHEP Ipc: A61P 31/04 20060101ALI20190910BHEP Ipc: A61P 31/00 20060101ALI20190910BHEP Ipc: A61P 31/06 20060101ALI20190910BHEP Ipc: A61K 38/08 20190101ALI20190910BHEP Ipc: A61P 43/00 20060101ALI20190910BHEP Ipc: A61P 33/06 20060101ALI20190910BHEP Ipc: A61P 33/00 20060101ALI20190910BHEP Ipc: A61P 7/06 20060101ALI20190910BHEP Ipc: A61P 3/00 20060101ALI20190910BHEP Ipc: A61K 38/10 20060101ALI20190910BHEP
2020-10-16	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2020-11-18	18D	Application deemed to be withdrawn	Effective date: 20200603

Publication	Publication Date	Title
EP3353210B8 (de)	2024-12-18	Anti-tigit-antikörper und verfahren zur verwendung
EP3259246A4 (de)	2018-10-03	Derivate von sobetirom
EP3245291A4 (de)	2018-09-19	Neuartige mikrodystrophine und zugehörige verfahren zur verwendung
EP3280441A4 (de)	2018-09-12	Anti-sortilin-antikörper und verfahren zur verwendung davon
EP3377070A4 (de)	2019-07-10	Verbindungen und verfahren zu deren verwendung
EP3116851A4 (de)	2017-08-16	Analoga von fexaramin und verfahren zur herstellung und verwendung
EP3240571A4 (de)	2018-06-13	Formulierung von aglycosylierten therapeutischen antikörpern
EP3207708A4 (de)	2017-11-29	Verfahren zur modifizierung von suchbereichen
EP3116898A4 (de)	2017-08-30	Verwendung von aav-exprimiertem m013-protein als entzündungshemmendes therapeutikum
EP3399996A4 (de)	2019-10-16	Verfahren zur verabreichung von hepcidin
EP3370728A4 (de)	2019-07-10	Verfahren und vorrichtung zur herstellung von obeticholsäure und derivaten davon
EP3289000A4 (de)	2018-10-31	Deoxydehydrierung von zuckerderivaten
EP3265476A4 (de)	2018-08-22	Protoxin-vii-varianten und verfahren zur verwendung
EP3270918A4 (de)	2018-10-24	Anti-met-antikörper und verfahren zur verwendung davon
EP3297619A4 (de)	2019-01-02	Therapeutische verwendung von l-4-chlorokynurenin
EP3277304A4 (de)	2018-12-19	Protoxin-vii-varianten und verfahren zur verwendung
EP3139956A4 (de)	2017-11-29	Verfahren zur verwendung von anti-ang2-antikörpern
EP3227298A4 (de)	2018-05-23	Verfahren zur herstellung von baricitinib und zwischenprodukten davon
EP3468578A4 (de)	2020-01-01	Verwendungen von il-41
EP3334730A4 (de)	2018-12-26	Pyrrolomycine und verfahren zur verwendung davon
EP3149024A4 (de)	2018-06-06	Derivate von dolaproin-dolaisoleuin-peptid
EP3541391A4 (de)	2020-06-17	Alkyl-pyrrolopyrimidin-analoga und verfahren zur herstellung und verwendung davon
EP3554508A4 (de)	2020-08-05	Pharmazeutische formulierungen von suvorexant
IL267227A (en)	2019-08-29	Methods of administering hepcidin
EP3289092A4 (de)	2018-12-12	Verfahren zur herstellung therapeutischer proteine